NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS) from its SEC filings: 2025 revenue $22.5 million (-51% vs the year before), net margin -902%, free cash flow -$147.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $22.5 million |
| Revenue growth | -51% |
| Net income | -$203.0 million |
| Net margin | -902.1% |
| Free cash flow | -$147.8 million |
| Diluted EPS | $-1.72 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -81% |
| Cash | $424.2 million |
| Share count, 1 year | +6% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.